Hyperpolarised Imaging Lung Facility, QMC, Uni of Nottingham
Nottingham, NG7 2UH, United Kingdom
NCT Number: NCT02976935
The aim of this study is to investigate the potential value of a novel imaging technique (hyperpolarized 129Xe lung imaging) in the diagnosis and assessment of lung disease in patients with COPD and IPF.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Nottingham, NG7 2UH, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
General Inclusion criteria
Inclusion criteria
HEALTHY VOLUNTEERS
PATIENTS
COPD
Exclusion criteria
HEALTHY VOLUNTEERS
PATIENTS
Hyperpolarised 129 Xe to assess lung function
Time frame: 4 years
i) Obtain baseline data for each group with matched clinical data (e.g. pulmonary function tests) allowing comparison with existing clinical diagnostic techniques and also determining correlation with disease severity ii) Use the images obtained to set up standard sequencing protocols and define algorithms and inform power calculations for subsequent studies
Time frame: 4 years
University of Nottingham
Other
FUNCTIONAL MAGNETIC RESONANCE LUNG IMAGING USING INHALED HYPERPOLARISED 129Xe
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05193136
Atrophy, Behavior
Jōyō, Kyoto, Japan
View Trial DetailsNCT03927820
Asthma, Bronchial Diseases
Nashville, Tennessee, United States
View Trial DetailsNCT06614959
Bronchial Diseases, Bronchitis
Montreal, Quebec, Canada
View Trial DetailsNCT04754490
COPD, Chronic Disease
Abercynon, Wales, United Kingdom
View Trial Details